{"id":"ropinirole-pr-xr","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dyskinesia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ropinirole works by binding to dopamine receptors in the brain, which helps to increase the amount of dopamine available for use. This can help to improve motor function and reduce symptoms of Parkinson's disease. Ropinirole is available in both immediate-release (PR) and extended-release (XR) formulations.","oneSentence":"Ropinirole PR/XR is a dopamine agonist that mimics the action of dopamine in the brain, helping to regulate movement and reduce symptoms of Parkinson's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:41.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Restless legs syndrome"}]},"trialDetails":[{"nctId":"NCT00434304","phase":"PHASE2","title":"Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-09","conditions":"Parkinson Disease","enrollment":62},{"nctId":"NCT00823836","phase":"PHASE3","title":"Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Parkinson Disease","enrollment":302}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ropinirole IR-PR group"],"phase":"phase_3","status":"active","brandName":"ropinirole PR/XR","genericName":"ropinirole PR/XR","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ropinirole PR/XR is a small molecule agonist that targets the D2-like dopamine receptor. It is used to treat Parkinson's disease, as indicated by clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}